Lucchi, M., Melfi, F., Dini, P., Basolo, F., Viti, A., Givigliano, F., et al. (2006) Neoadjuvant Chemotherapy for Stage III and IVA Thymomas: A Single-Institution Experience with a Long Follow-Up. Journal of Thoracic Oncology, 1, 308-313.
https://doi.org/10.1016/S1556-0864(15)31586-0

has been cited by the following article:

• TITLE: Survival in a Chilean Cohort of Thymic Tumors

  AUTHORS: Mauricio Salinas, Mozart Liessi, Patricio Vallejo, Cristian Ibarra

  KEYWORDS: Thymoma, Thymus Neoplasms, Thymus Gland

  JOURNAL NAME: Journal of Cancer Therapy, Vol.10 No.7, July 10, 2019

  ABSTRACT: Introduction: Thymus neoplasm is rare tumors and it has low mortality. There are scarce publications in Latin-American about this topic. We present a Chilean casuistic. Method: Retrospective cohort of every patient’s thymic epithelial tumors diagnosed in Instituto Nacional del Tórax, Santiago, Chile, between January 2007 and June 2015. Information was obtained from pathological and clinical registries. Death date was achieved from national registry. We report epidemiological data, clinical manifestations, histology type, Masaoka and WHO classification, therapies and survivor. Results: Sixty-five patients were included, with mean age 58 years and 36.9% men. Myasthenia gravis was present in 24 (36.9%) of patients. Ninety four percent of patients had a surgical biopsy. There were 60 thymomas and 5 thymic carcinomas. Most of tumors were stage I and II in Masaoka classification and type B in WHO classification. There were no deaths at 30 days. Nosocomial pneumonia was the most common complication. Conclusions: In this thymic tumor cohort there are more women and they are older than previously reported. Myasthenia gravis prevalence was similar. The survival of patients with thymomas was excellent.